ELUT: Gunggunge utang jangka dawa Elutia Inc

Elutia Inc. (ELUT) generates revenue from the creation of biomedical devices, including high-margin antimicrobial coatings and orthopedic grafts. The asset's market dynamics on GURU.Markets show a value of 0.00. Successes with the CanGaroo shell and new FDA approvals are driving the company's growth. Meanwhile, management is currently optimizing internal processes following the implementation of bioplatforms, maintaining shareholder confidence through expansion in the bioprosthetics segment.

ELUT Elutia Inc.: Utang jangka dawa perusahaan ing interval 21.02.2024 - 29.10.2026

Rincian analitis perusahaan Elutia Inc.

- rega lan prakiraan konsensus rega:

Kurs saham elutia.com|ELUT - Prakiraan konsensus analis

- data kapitalisasi pasar:

Kapitalisasi pasar Elutia|ELUT - Nilai Perusahaan

- data kapitalisasi buku:

Nilai Akuntansi saben Saham Elutia|ELUT - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku elutia.com|ELUT - Aset Agregat Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas Elutia Inc.|ELUT - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Elutia Corporation|ELUT - Gunggung utang perusahaan|Utang-utang marang aset resik Elutia|ELUT - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Elutia

Analisis umum perusahaan:elutia.com (ELUT)

For Elutia Inc. (ELUT), a leader in anti-infective implants with premium pricing power, the company's long-term debt statistics reflect its innovation financing strategy. This indicator aggregates all liabilities with maturities exceeding one year, allowing for an assessment of the debt load without accounting for quarterly lags, where excessive growth in the loan portfolio could offset high operating margins and reduce the overall resilience of the asset.

Analisis pesaing